Aurinia Pharmaceuticals Inc. (TSE:AUP – Get Free Report) (NASDAQ:AUPH)’s share price was down 3.5% during trading on Monday . The stock traded as low as C$16.41 and last traded at C$16.76. Approximately 4,611,683 shares were traded during mid-day trading, an increase of 1,906% from the average daily volume of 229,895 shares. The stock had previously closed at C$17.37.
Aurinia Pharmaceuticals Price Performance
The company has a quick ratio of 11.02, a current ratio of 11.93 and a debt-to-equity ratio of 2.69. The company’s fifty day simple moving average is C$16.76. The company has a market capitalization of C$2.15 billion and a PE ratio of -11.32.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Further Reading
- Five stocks we like better than Aurinia Pharmaceuticals
- What Are Dividend Achievers? An Introduction
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- What Are the FAANG Stocks and Are They Good Investments?
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
